Ballentine Partners LLC Acquires 89,263 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Ballentine Partners LLC increased its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 577.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,715 shares of the company's stock after purchasing an additional 89,263 shares during the quarter. Ballentine Partners LLC's holdings in Dr. Reddy's Laboratories were worth $1,653,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in RDY. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Dr. Reddy's Laboratories by 318.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company's stock worth $28,411,000 after purchasing an additional 283,700 shares in the last quarter. Artemis Investment Management LLP boosted its stake in Dr. Reddy's Laboratories by 398.3% during the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company's stock valued at $4,666,000 after buying an additional 236,224 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Dr. Reddy's Laboratories by 59.4% during the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company's stock valued at $39,034,000 after buying an additional 183,146 shares during the last quarter. Millennium Management LLC boosted its stake in Dr. Reddy's Laboratories by 61.4% during the second quarter. Millennium Management LLC now owns 332,502 shares of the company's stock valued at $25,333,000 after buying an additional 126,472 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Dr. Reddy's Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock valued at $76,455,000 after buying an additional 114,294 shares during the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 1.7 %

Shares of NYSE:RDY traded up $0.26 during trading on Wednesday, hitting $15.06. The company had a trading volume of 3,461,539 shares, compared to its average volume of 2,335,888. The stock has a market cap of $12.57 billion, a price-to-earnings ratio of 24.05 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a one year low of $13.52 and a one year high of $16.89. The company has a fifty day simple moving average of $14.86 and a two-hundred day simple moving average of $15.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. Barclays lowered their price objective on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Finally, StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.